Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer&#039;s disease (GuidAge): a randomised placebo-controlled trial by B. Vellas et al.
Long-term use of standardised ginkgo biloba extract for the
prevention of Alzheimer's disease (GuidAge): a randomised
placebo-controlled trial
Submitted by Emmanuel Lemoine on Wed, 04/22/2015 - 16:57
Titre Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer'sdisease (GuidAge): a randomised placebo-controlled trial
Type de
publication Article de revue
Auteur
Vellas, B. [1], Coley, N. [2], Ousset, P. J [3], Berrut, Gilles [4], Dartigues, J. F [5],
Dubois, B. [6], Grandjean, H. [7], Pasquier, F. [8], Piette, F. [9], Robert, Pierre-
Emmanuel [10], Touchon, J. [11], Garnier, P. [12], Mathiex-Fortunet, H. [13], Andrieu,
S. [14], GuidAge Study Group [15]
Editeur Elsevier











decline [16], Dementia [17], Design [18], double-blind [19], educational-level [20],




Background Prevention strategies are urgently needed to tackle the growing burden
of Alzheimer's disease. We aimed to assess efficacy of long-term use of standardised
ginkgo biloba extract for the reduction of incidence of Alzheimer's disease in elderly
adults with memory complaints.Methods In the randomised, parallel-group, double-
blind, placebo-controlled GuidAge clinical trial, we enrolled adults aged 70 years or
older who spontaneously reported memory complaints to their primary-care physician
in France. We randomly allocated participants in a 1:1 ratio according to a computer-
generated sequence to a twice per day dose of 120 mg standardised ginkgo biloba
extract (EGb761) or matched placebo. Participants and study investigators and
personnel were masked to study group assignment. Participants were followed-up for
5 years by primary-care physicians and in expert memory centres. The primary
outcome was conversion to probable Alzheimer's disease in participants who received
at least one dose of study drug or placebo, compared by use of the log-rank test. This
study is registered with ClinicalTrials.gov, number NCT00276510. Findings Between
March, 2002, and November, 2004, we enrolled and randomly allocated 2854
participants, of whom 1406 received at least one dose of ginkgo biloba extract and
1414 received at least one dose of placebo. By 5 years, 61 participants in the ginkgo
group had been diagnosed with probable Alzheimer's disease (1.2 cases per 100
person-years) compared with 73 participants in the placebo group (1.4 cases per 100
person-years; hazard ratio [FIR] 0.84, 95% CI 0.60-1.18; p=0.306), but the risk was
not proportional over time. Incidence of adverse events was much the same between
groups. 76 participants in the ginkgo group died compared with 82 participants in
the placebo group (0.94, 0.69-1. 28; p=0.68). 65 participants in the ginkgo group had
a stroke compared with 60 participants in the placebo group (risk ratio 1.12, 95% CI
0.77-163; p=0.57). Incidence of other haemorrhagic or cardiovascular events also did
not differ between groups. Interpretation Long-term use of standardised ginkgo
biloba extract in this trial did not reduce the risk of progression to Alzheimer's
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